Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexsero in Adult Patients With Asplenia
2023-508192-36-00Phase 2Authorised
- Sponsor
- Medical University of Vienna
- Start
- Mar 2024
- Countries
- 1
01
Overview
Phase 2, open-label trial of meningococcal group B vaccine in meningococcal disease (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Mean log-titre over three meningococcal strains by hSBA one month after second vaccination. Planned start Mar 2024; status: authorised.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2023-508192-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508192-36-00.